Tracers / [188Re]Re-MAG3
[188Re]Re-MAG3
Also written as [Re-188]MAG3; Re-188-MAG3
- Radionuclide
- Re-188 t½ 1020 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 3
What it is
- Compound class
- —
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | [188Re]-perrhenate | 11272362 1999 Cardiovasc Radiat Med Rhenium-188-labeled benzoylthioacetyltriglycine (MAG3) was prepared by stannous ion reduction of [188Re]-perrhenate in the presence of the benzyl-MAG3 substrate |
| — | — | SPE | 80-85% | — | commercial kit and reducing agents | 11214876 2001 Appl Radiat Isot Routine production of 188Re-MAG3 for use in intracoronary radiation therapy was performed by compressed air driven semi-automated shielded system. — reproducible radiolabeling yields of 80-85% were obtained |
| — | — | — | — | — | — | 10698233 2000 J Nucl Cardiol |
Need this precursor?We can point you to suppliers for [188Re]Re-MAG3, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.